# 2025-15155: Galephar Pharma Seeks Federal Approval for Importing Regulated Substances

2025-15155, Importer of Controlled Substances Application: Galephar Pharmaceutical Research Inc, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-08-11 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-15155
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-15155
- Title: Importer of Controlled Substances Application: Galephar Pharmaceutical Research Inc
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 38667
- Published: 2025-08-11
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Galephar Pharma Seeks Federal Approval for Importing Regulated Substances

## Summary

Galephar Pharmaceutical Research Inc wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that need special handling. If approved, this could affect companies and regulators keeping an eye on drug imports, with no immediate cost changes announced.

## Abstract

Galephar Pharmaceutical Research Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-15155 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/11/2025-15155/importer-of-controlled-substances-application-galephar-pharmaceutical-research-inc)
- [2025-15155 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-11/pdf/2025-15155.pdf)

## Related
- [Previous: 2025-15154, Applications for New Awards; Assistance for Arts Education Program](https://policyrisk.com/federal-register/2025-15154)
- [Next: 2025-15156, Importer of Controlled Substances Application: Curia New York Inc](https://policyrisk.com/federal-register/2025-15156)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-15155 (as of 2026-06-08).